Press release

American Kidney Fund Statement on ESRD Final Rule

AKF President and CEO LaVarne A. Burton's statement on the Centers for Medicare & Medicaid Services Calendar Year 2024 End-Stage Renal Disease Prospective Payment System Final Rule

ROCKVILLE, Md. (Oct. 31, 2023) The American Kidney Fund (AKF) is disappointed that the Centers for Medicare & Medicaid Services (CMS) Calendar Year 2024 End-Stage Renal Disease (ESRD) Prospective Payment System (PPS) Final Rule, released on Oct. 27, does not take into account serious patient issues raised by AKF and others in the kidney care community. This final rule updates payment rates and policies for dialysis services for Medicare beneficiaries.

LaVarne A. Burton, AKF President and CEO, today issued this statement:

"We are deeply disappointed that CMS has failed to fully address critically important concerns raised by the American Kidney Fund and many other stakeholders in the kidney community during the rulemaking process. AKF remains concerned about the ramifications of CMS not adequately accounting for staffing shortages facing dialysis providers and not appropriately addressing long-term access to innovative drugs.

"This is a health equity issue because ultimately, the people who will be hurt the most by CMS' shortsighted final rule are those who are very sick and live in underserved communities. Staffing shortages will adversely impact access to care for people who rely on life-sustaining dialysis treatments. We cannot emphasize strongly enough how concerned we are about the real-life impact this rule will have on patients.

"We urge Members of Congress to support the Chronic Kidney Disease Improvement in Research and Treatment Act of 2023 (H.R. 5027), which contains provisions that would expand kidney disease prevention, screening and education efforts; ensure accurate and stable provider payments to help address the workforce crisis in kidney care; and provide a long-term and sustainable payment pathway to ensure patient access to innovative drugs, biologicals, devices and other technologies."

About the American Kidney Fund

The American Kidney Fund (AKF) fights kidney disease on all fronts as the nonprofit with the greatest direct impact on people with kidney disease. AKF works on behalf of 1 in 7 Americans living with kidney disease, and the millions more at risk, with an unmatched scope of programs that support people wherever they are in their fight against kidney disease—from prevention through transplant. AKF fights for kidney health for all through programs that address early detection, disease management, financial assistance, clinical research, innovation and advocacy. AKF is one of the nation’s top-rated nonprofits, investing 97 cents of every donated dollar in programs, and holds the highest 4-Star rating from Charity Navigator for 21 consecutive years and the Platinum Seal of Transparency from Candid, formerly known as GuideStar. 

For more information, please visit, or connect with us on Facebook, Twitter, Instagram and LinkedIn.